Terbinafine-Induced Subacute Cutaneous Lupus Erythematosus

Farhi, David; Viguier, Manuelle; Cosnes, A.; Reygagne, P.; Dubertret, Louis; Revuz, J; Roujeau, Jean‐Claude; Bachelez, Hervé

doi:10.1159/000089024

Cited by 36 publications

(20 citation statements)

References 56 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…To the authors’ knowledge, this type of reaction has never been reported before in cats. However, multiple and often serious, skin reactions such as erythema multiforme, erythroderma, urticaria, and subacute cutaneous lupus erythematosus have been reported in humans treated with terbinafine 21,22 . Importantly, these cats developed the cutaneous reaction after discontinuing the terbinafine.…”

Section: Discussionmentioning

confidence: 99%

Evaluation of persistence of terbinafine in the hair of normal cats after 14 days of daily therapy

Foust¹,

Marsella²,

Akucewich³

et al. 2007

Veterinary Dermatology

View full text Add to dashboard Cite

This study determined the residual concentration of terbinafine in cat hair after 14 days of oral treatment. Ten clinically normal cats were administered terbinafine orally at a daily dose of 34-45.7 mg kg(-1) for a total of 14 days. Areas of 15 cm(2) were shaved on the lateral thorax at day 0 and weekly for 8 weeks after the last dose of terbinafine. The hair samples were analysed by high-pressure liquid chromatography to determine the persistence of terbinafine over time. The mean terbinafine concentration in hair was 2.30 ng mg(-1) after 14 days of therapy. The half life was 1.84 weeks after the last dose of terbinafine. With a 99% confidence interval, the concentration of terbinafine remained in the cat hair at or above 0.03 ng mg(-1) (minimal inhibitory concentration (MIC)(90) = 0.03 microg mL(-1)) for 5.3 weeks. Slight deviations in the complete blood cell count and serum chemistry values were not attributed to terbinafine. Four cats experienced vomiting during the terbinafine treatment; two of these cats also experienced intense facial pruritus followed by a macular to papular skin reaction 7-14 days after the discontinuation of terbinafine. In summary, terbinafine persists in hair at concentrations above the MIC for several weeks after stopping medication, even after short-term therapy (14 days). These results suggest that pulse therapy of terbinafine should be further researched and potentially considered as a treatment modality for feline dermatophytosis, an approach that would decrease treatment duration while maintaining effectiveness.

show abstract

Section: Discussionmentioning

confidence: 99%

Evaluation of persistence of terbinafine in the hair of normal cats after 14 days of daily therapy

Foust¹,

Marsella²,

Akucewich³

et al. 2007

Veterinary Dermatology

View full text Add to dashboard Cite

show abstract

“…Anti-SSA/Ro-associated drug-induced LE is believed to be an entity distinct from classical drug-induced LE, because the former is characterized primarily by cutaneous disease and lacks antihistone antibodies [5]. The causal drugs for this disease are variable, such as hydrochlorothiazide, calcium channel blockers, angiotensin-converting enzyme inhibitors, griseofulvin and terbinafine [5,7,8,9]. It is well known that FU agents induce DLE-like eruptions in Japan [1].…”

Section: Discussionmentioning

confidence: 99%

Anti-SSA/Ro Antibody as a Risk Factor for Fluorouracil-Induced Drug Eruptions Showing Acral Erythema and Discoid-Lupus-Erythematosus-Like Lesions

Adachi¹,

Nagai²,

Horikawa³

2006

Dermatology

View full text Add to dashboard Cite

Background: It is well known that fluorouracil (FU) agents frequently induce discoid-lupus-erythematosus (DLE)-like eruptions and acral erythema in Japan. However, the etiology of these drug eruptions caused by FU agents has not been clarified yet. Objective: To determine if the existence of anti-SSA/Ro antibody may be a risk factor for FU-agent-induced DLE-like eruptions and acral erythema. Patients and Methods: Six patients with FU-agent-induced drug eruptions showing DLE-like lesions and acral erythema were enrolled in this study. The titers of anti-SSA/Ro antibody in the sera and the histopathology of the skin lesions were examined. Results: Biopsy specimens from DLE-like eruptions and all 5 examined acral erythema cases showed lichenoid change of the basal keratinocytes. Direct immunofluorescence studies revealed deposition of immunoglobulins along the basement membrane zone in the lesions of both DLE-like eruptions and acral erythema. Further, all 6 cases had high titers of serum anti-SSA/Ro antibody, which did not decline within 6 months after cessation of the causative drug. Conclusion: We propose that anti-SSA/Ro antibody may be a risk factor for FU-agent-induced drug eruptions showing acral erythema and DLE-like eruptions.

show abstract

“…In all three, along with positive ANA, patients also had antibodies to Ro/SS-A and/or La/SS-B, as is characteristic in SCLE. Including the patient described here, there are currently (as of April 2008) 28 reports in the English, French, and German literature of terbinafine-induced LE ( Table 1; [4][5][6][7][8][9][10][11][12][13][14][15]). In one patient, there was concomitant onset of Stevens-Johnson syndrome [13]; in all patients, the skin lesions and/or documented antibody status are compatible with the presence of SCLE.…”

Section: Discussionmentioning

confidence: 99%

Subacute cutaneous lupus erythematosus induced by terbinafine: case report and review of literature

Lorentz

Booken

Goerdt

et al. 2008

J Deutsche Derma Gesell

View full text Add to dashboard Cite

Systemic lupus erythematosus and subacute cutaneous lupus erythematosus (SCLE) occasionally evolve as adverse reactions to a large variety of chemically different drugs. We here report on a 76-year-old woman who developed SCLE within 10 days after initiation of oral terbinafine. Analysis of the 27 cases of terbinafine-induced SCLE in the literature revealed that this disorder has been reported 6 times more often in females than in males. Skin lesions evolved on average around 7 weeks after starting the drug. In 79% of the cases ANA could be detected while antibodies against Ro/SS-A and La/SS-B were found in 86% and 39%, respectively. Remarkably, anti-histone antibodies were present in only 29%. In all cases terbinafine-induced SCLE resolved after discontinuation of the triggering agent. Systemic treatment with anti-malarials and/or corticosteroids does not appear to be mandatory.

show abstract

Terbinafine-Induced Subacute Cutaneous Lupus Erythematosus

Cited by 36 publications

References 56 publications

Evaluation of persistence of terbinafine in the hair of normal cats after 14 days of daily therapy

Evaluation of persistence of terbinafine in the hair of normal cats after 14 days of daily therapy

Anti-SSA/Ro Antibody as a Risk Factor for Fluorouracil-Induced Drug Eruptions Showing Acral Erythema and Discoid-Lupus-Erythematosus-Like Lesions

Subacute cutaneous lupus erythematosus induced by terbinafine: case report and review of literature

Contact Info

Product

Resources

About